Research study on "Risks for Pfizer" - GRM Institute

Research study on “Risks for Pfizer”


By Aditya Sai & Shubhangini Dwivedi (PGDRM Batch Jan’21-22)


  • Pfizer Inc. is an American multinational pharmaceutical corporation, headquartered in Manhattan, New York.​
  • ​Founders are Charles Pfizer and Charles F.Erhart and founded in 1849.​
  • ​Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.​​
  • The company has several blockbuster drugs or products that each generate more than US$1 billion in annual revenues.​
  • Revenue: 51.8 billion dollars.​
  • ​The number of Employees are 88300.


  1. Prevenar13​
  2. Lyrica​
  3. Dolonex​
  4. MiniPress xl​
  5. Picojoules Range​
  6. Folvite​
  7. Magnex​
  8. Autrin​
  9. Ativan​
  10. Corex Range​
  11. Mucain​
  12. Gelusil​
  13. Zinforo​
  14. Zavicefta​
  15. Ovral L​
  16. Neksium​
  17. Citralka​
  18. Wysolone​
  19. Eliquis​
  20. Meronem

Business Risks
  • Research  And Development
  • Spends huge amounts in terms of R&D, there are huge risks like interim developmental failure, improper allocation for products, lack of regulatory approval for researched product, and also researched products may not be huge commercial success future.​

  • Concentration Risk
  • Pfizer recorded direct product and/or alliance revenues, of more than $1 billion for each of seven products that collectively accounted for 53%.​
  • If these products were to face challenges like, loss of patent protection (if applicable), changes in prescription growth rates, unexpected side effects, or safety concerns, the adverse impact on Pfizer’s revenues could be significant.​
Competition Risks
  • Competition from manufacturers of generic drugs, including from generic versions of competitors’ branded products that lose their market exclusivity, is a major challenge for Pfizer’s branded products.​
  •  A few products have experienced significant generic competition in the last few years. For example, the basic product patent for Chantix in the U.S. expired in November 2020. While the multi-source generic competition for Chantix has not yet begun, it could commence soon.​
  • In China, Pfizer is continuing to face intense competition by certain generic manufacturers, which may result in price cuts and volume loss of some of our products.​
  • Pfizer can become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars.​
Operational Risks

Product Manufacturing, Sales And Marketing Risks

  • Delays in product manufacturing, sales, or marketing due to shut-downs or strikes, approval delays, withdrawals, recalls, damage to ………….

Read the full research study here: Risks for Pfizer by Aditya Sai and Subhangini


This report has been produced by students of Global Risk Management Institute for their own research, classroom discussions and general information purposes only. While care has been taken in gathering the data and preparing the report, the student’s or GRMI does not make any representations or warranties as to its accuracy or completeness and expressly excludes to the maximum extent permitted by law all those that might otherwise be implied. References to the information collected have been given where necessary.

GRMI or its students accepts no responsibility or liability for any loss or damage of any nature occasioned to any person as a result of acting or refraining from acting as a result of, or in reliance on, any statement, fact, figure or expression of opinion or belief contained in this report. This report does not constitute advice of any kind.


Design and Developed by KodeForest @ All Rights Reserved by KodeForest